SCHEMBL6672865

SCHEMBL6672865

CCCC1CCN(c2ccc(CN)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 4/20 0.43
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38
L3MBTL3 Q96JM7 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
DPP4 P27487 2/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
RAD52 P43351 1/20 0.37
GFER P55789 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BPTF Q12830 1/20 0.36
MBTD1 Q05BQ5 1/20 0.36
TP53BP1 Q12888 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25189163 0.92 SMN1; SMN2 (0.39) TPSAB1HRH3L3MBTL3L3MBTL1KDM4E
SCHEMBL22794821 0.87 KDM4E (0.46) MAOAMAOBHRH3L3MBTL3L3MBTL1
SCHEMBL25833691 0.85 MAOB (0.52) MAOAMAOBHRH3L3MBTL3L3MBTL1
SCHEMBL25188789 0.83 MAPT (0.54) HRH3L3MBTL3L3MBTL1DPP4KDM4E
SCHEMBL7914429 0.81 SLC6A2 (0.48) HRH3L3MBTL3L3MBTL1DPP4MAPT
SCHEMBL156068 0.81 ADRB1 (0.47) MAOBHRH3L3MBTL3L3MBTL1GAA
SCHEMBL23806804 0.81 ALDH1A1 (0.40) MAOAMAOBHRH3L3MBTL3L3MBTL1
SCHEMBL27629259 0.80 KDM4E (0.46) MAOBKDM4EGAAMAPTSMN1; SMN2
SCHEMBL4027191 0.80 USP2 (0.53) TPSAB1HRH3L3MBTL3L3MBTL1KDM4E
SCHEMBL25193288 0.79 SMN1; SMN2 (0.41) TPSAB1HRH3L3MBTL3L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465613-A2 COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2004-10-13 EP disclosed
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed
WO-2003057205-A2 COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-07-17 WO disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed
WO-2003004020-A1 HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN TPSAB1 1874/4885MAOA 1988/4885MAOB 1418/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 TPSAB1 598/4885MAOA 832/4885MAOB 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.